Recombinant Brucella abortus Methionyl-tRNA formyltransferase (fmt)

What is Methionyl-tRNA formyltransferase (fmt) and why is it important in Brucella abortus?

Methionyl-tRNA formyltransferase (fmt) is an enzyme that catalyzes the formylation of methionyl-tRNA, which is essential for protein synthesis initiation in bacteria. In Brucella abortus, fmt is particularly important because it represents a potential drug target due to its essential role in bacterial metabolism. Similar to Methionyl-tRNA-Synthetase (MetRS), which has been identified as a potential drug target for brucellosis, fmt is involved in the protein synthesis pathway and may offer opportunities for targeted drug development . The enzyme operates within the bacterial translation machinery, which is distinct from eukaryotic systems, making it an attractive target for antimicrobial development without affecting host cells.

How does recombinant B. abortus fmt compare structurally with other bacterial formyltransferases?

Recombinant B. abortus fmt shares structural similarities with other bacterial formyltransferases but has species-specific characteristics. Like the related MetRS enzyme, which contains a catalytic domain formed by a Rossmann fold, connective peptide (CP) domain, stem-contact fold (SCF) domain, and an anti-codon binding α-helix bundle, fmt likely has conserved functional domains with unique structural features . The enzyme contains binding sites for its substrates (methionyl-tRNA and formyl donor) that can be targeted by inhibitors. Structural analysis through X-ray crystallography and computational modeling has revealed potential binding pockets that differ from homologous enzymes in other bacterial species, offering opportunities for selective targeting.

What expression systems are most effective for producing recombinant B. abortus fmt?

Several expression systems have been employed for producing recombinant B. abortus proteins, with E. coli-based systems being the most commonly used due to their high yield and relative simplicity. Based on approaches used for other Brucella proteins, pCold-TF vector systems have shown success in expressing soluble, functional Brucella proteins, including those used in subunit vaccine development . For optimal expression of B. abortus fmt, considerations must include:

• Selection of appropriate E. coli strains (BL21(DE3), Rosetta, or Arctic Express)

• Optimization of induction conditions (temperature, IPTG concentration, duration)

• Addition of solubility-enhancing fusion tags (e.g., TF tag, which has demonstrated immunogenicity in experimental settings)

• Purification strategy typically involving immobilized metal affinity chromatography

While the pCold-TF vector can induce immune responses itself due to its trigger factor component, it provides advantages for protein folding and solubility that outweigh this consideration for research applications .

How can recombinant B. abortus fmt be used in drug discovery pipelines?

Recombinant B. abortus fmt can serve as a valuable tool in drug discovery pipelines through multiple approaches:

• High-throughput screening platforms: Purified recombinant fmt can be used in enzymatic assays to screen compound libraries for potential inhibitors. Similar to the approach used with B. melitensis MetRS, where compounds like 1312 demonstrated binding and induced conformational changes, fmt inhibition assays can identify molecules that disrupt its activity .

• Structure-based drug design: Crystal structures of fmt in complex with substrates or inhibitors can guide rational design of novel compounds. The observed movement of domains upon ligand binding, as seen with MetRS and compound 1312, provides insights into potential allosteric inhibition mechanisms .

• Fragment-based approaches: Small molecular fragments can be screened for binding to fmt using techniques such as thermal shift assays, NMR, or X-ray crystallography, followed by fragment growing or linking strategies.

• In silico methods: Virtual screening and molecular dynamics simulations can identify and optimize potential inhibitors before experimental validation.

A methodological pipeline would involve:

• Initial screening of compound libraries

• Hit validation using secondary assays

• Structure-activity relationship studies

• In vitro testing against live Brucella strains

• Animal model validation using established infection protocols similar to those used for testing subunit vaccines

What immunological properties does recombinant B. abortus fmt exhibit and how might it be incorporated into subunit vaccine strategies?

Recombinant B. abortus fmt may serve as a potential immunogen in subunit vaccine development. While specific data on fmt is limited in the search results, research on other B. abortus recombinant proteins demonstrates the potential for such applications. Based on immunological studies of other B. abortus proteins:

• T cell responses: Like other B. abortus proteins, fmt likely contains epitopes that can induce T helper 1 (Th1) responses, which are crucial for controlling intracellular infections. The predominant Th1 response (characterized by high IFN-γ production) observed with other B. abortus recombinant proteins suggests that fmt could similarly stimulate protective cell-mediated immunity .

• Antibody responses: Recombinant B. abortus proteins have been shown to induce specific antibody responses, particularly IgG2a (indicative of Th1 responses) rather than IgG1 (associated with Th2 responses), which correlates with protection against B. abortus challenge .

• Incorporation into multi-antigen formulations: As demonstrated with the combined subunit vaccine (CSV) approach using Omp16, Omp19, Omp28, and L7/L12, fmt could potentially be incorporated into multicomponent vaccines to enhance protective efficacy. The CSV approach showed superiority over single antigen formulations in inducing protection against B. abortus challenge .

How do mutations in B. abortus fmt affect bacterial virulence and intracellular survival?

Mutations in B. abortus fmt likely impact bacterial virulence and intracellular survival through several mechanisms:

• Protein synthesis efficiency: Fmt is essential for efficient initiation of protein synthesis in bacteria. Mutations may lead to reduced translation efficiency, particularly affecting virulence factors necessary for survival within host macrophages.

• Stress response: Fmt mutations may compromise bacterial adaptation to intracellular stresses, including oxidative stress within macrophages, similar to how modifications in other translation-related factors affect bacterial fitness.

• Host immune evasion: Altered protein synthesis may impact the expression of factors involved in modulating host immune responses, potentially making mutants more susceptible to bactericidal mechanisms like those observed in CSV-treated RAW 264.7 cells .

Experimental evidence from mouse infection models with other Brucella mutants suggests that fmt-deficient strains would likely show reduced splenic colonization similar to what was observed in studies comparing wild-type and recombinant protein-treated groups, where bacterial loads were significantly reduced in vaccinated animals .

What are the optimal conditions for expressing and purifying recombinant B. abortus fmt?

Based on protocols used for other Brucella recombinant proteins, the following optimization strategy is recommended for B. abortus fmt:

Expression system optimization:

• Vector selection: pCold-TF or pET series vectors with appropriate fusion tags (His, GST, or TF) to enhance solubility

• E. coli strain: BL21(DE3), Rosetta, or Arctic Express for efficient expression of potentially toxic bacterial proteins

• Culture conditions:

  • Initial growth at 37°C to OD600 of 0.5-0.8

  • Temperature reduction to 15-18°C prior to induction with IPTG (0.1-0.5 mM)

  • Extended expression period (16-20 hours) at reduced temperature

Purification protocol:

• Cell lysis using sonication or French press in buffer containing 50 mM Tris-HCl (pH 8.0), 300 mM NaCl, 10% glycerol, and protease inhibitors

• Initial purification via IMAC (immobilized metal affinity chromatography) using Ni-NTA resin

• Secondary purification step using ion exchange or size exclusion chromatography

• Quality assessment through SDS-PAGE, Western blotting with Brucella-positive serum, and enzymatic activity assays

Enzymatic activity assay:
A spectrophotometric assay monitoring the formation of formylmethionyl-tRNA through measurement of tetrahydrofolate oxidation or direct quantification of formylated Met-tRNA using HPLC analysis.

What animal models are most appropriate for studying B. abortus fmt as a vaccine candidate or drug target?

Several animal models can be utilized for studying B. abortus fmt, with specific advantages and limitations:

Mouse models:

• BALB/c mice:

  • Widely used for initial vaccine and drug efficacy studies

  • Administration route: Intraperitoneal (IP) injection (2 × 10^5 CFUs of virulent B. abortus)

  • Evaluation timepoints: Typically 1-8 weeks post-challenge

  • Assessment parameters: Splenic bacterial loads, cytokine profiles (IFN-γ, IL-12, TNF-α), antibody titers (IgG1, IgG2a)

  • Advantages: Cost-effective, reproducible, well-characterized immune responses

  • Limitations: Not natural hosts for B. abortus

• C57BL/6 mice:

  • Alternative mouse strain with different immunological characteristics

  • Useful for studying specific immunological pathways using knockout variants

Large animal models:

• Bovine model:

  • Natural host for B. abortus

  • More relevant for translational studies

  • Assessment parameters: Prevention of abortion, protection against challenge, bacterial clearance

  • Limitations: Higher cost, greater ethical considerations, longer experiment duration

For initial fmt studies, the BALB/c mouse model with immunization schedule similar to that used for CSV (three immunizations at weeks 0, 2, and 5) followed by challenge at week 7 would be appropriate . A typical immunization protocol would involve:

• 100 μg of recombinant fmt protein mixed with incomplete Freund's adjuvant (IFA)

• IP administration in a total volume of 200 μL

• Challenge with virulent B. abortus strain (2 × 10^5 CFUs)

• Evaluation of bacterial loads, cytokine profiles, and antibody responses

How can genetic modification techniques be applied to study fmt function in B. abortus?

Several genetic approaches can be employed to study fmt function in B. abortus:

1. Conditional knockout strategies:
Since fmt is likely essential for bacterial viability, conditional knockout systems are preferable:

• Tetracycline-regulated expression systems

• Temperature-sensitive promoters

• CRISPR interference (CRISPRi) for transcriptional repression

2. Site-directed mutagenesis:
Generating specific mutations in the fmt gene to study structure-function relationships:

• Active site mutations to identify critical residues

• Substrate binding site alterations

• Regulatory domain modifications

3. Genomic insertion techniques:
Similar to the Tn7 transposon system used to insert the wbdR gene in B. abortus , the fmt gene can be modified by:

• Introduction of epitope tags for localization studies

• Reporter gene fusions to study expression patterns

• Complementation studies using wild-type or mutant variants

4. Heterologous expression:
Expression of fmt variants in compatible systems:

• Replacement of native fmt with homologs from other species

• Introduction of modified fmt genes with altered substrate specificity

These genetic modifications can be assessed through:

• Growth curve analysis under various stress conditions

• Intracellular survival in macrophage cell lines (e.g., RAW 264.7)

• Global proteomic analysis to identify changes in protein expression

• Virulence assessment in animal models

The techniques established for O-PS modification in B. abortus, where wbdR was introduced and wbkC deleted, provide a methodological framework for similar genetic manipulations of fmt .

How should researchers interpret discrepancies in fmt inhibition data between in vitro enzymatic assays and whole-cell antibacterial testing?

Researchers may encounter discrepancies between fmt inhibition in purified enzyme assays versus whole-cell antibacterial effects. These discrepancies should be systematically analyzed using the following framework:

Potential causes of discrepancies:

• Membrane permeability barriers:

  • Brucella species have complex cell envelopes that may limit inhibitor penetration

  • Compounds showing strong enzymatic inhibition may fail to reach intracellular targets

  • Solution: Chemical modification to enhance membrane permeability or coupling with delivery systems

• Efflux mechanisms:

  • Active efflux of compounds by bacterial pumps may reduce intracellular concentration

  • Analysis: Compare activity in the presence/absence of efflux pump inhibitors

• Metabolic modification:

  • Bacterial enzymes may modify inhibitors, reducing their efficacy

  • Assessment: Conduct metabolic stability studies in bacterial lysates

• Target essentiality in different conditions:

  • The importance of fmt may vary between in vitro growth and intracellular infection

  • Approach: Compare inhibitor effects in different growth media and within macrophage infection models

• Compensatory mechanisms:

  • Alternative pathways may compensate for fmt inhibition in whole cells

  • Investigation: Transcriptomic or proteomic analysis to identify upregulated pathways

A methodical approach to resolving such discrepancies would involve systematic modification of lead compounds guided by structure-activity relationship studies, similar to approaches used with MetRS inhibitors .

What statistical approaches are appropriate for analyzing immune responses to recombinant B. abortus fmt in vaccination studies?

Statistical analysis of immune responses to recombinant B. abortus fmt should follow rigorous approaches similar to those used in other Brucella vaccine studies:

Recommended statistical methods:

• For comparing bacterial loads:

  • Mann-Whitney U test or Kruskal-Wallis test (with Dunn's post-hoc) for non-normally distributed CFU data

  • Log-transformation of bacterial counts may be necessary before parametric testing

  • Data presentation as mean ± standard error with individual data points shown

• For cytokine analysis:

  • Student's t-test or one-way ANOVA with appropriate post-hoc tests (Tukey or Bonferroni) for normally distributed data

  • Correlation analysis between cytokine levels and protection measures

  • Multivariate analysis to identify cytokine patterns associated with protection

• For antibody responses:

  • Paired t-tests for comparing pre- and post-vaccination titers

  • ANOVA for comparing multiple groups

  • Analysis of IgG subclass ratios (IgG2a/IgG1) using paired tests

• For survival analysis:

  • Kaplan-Meier survival curves with log-rank tests when applicable

Sample size calculations:
Based on previous Brucella vaccination studies, group sizes of at least 5-10 animals per experimental condition are typically required to achieve statistical power of 0.8 with α=0.05 . Power analysis should be conducted using preliminary data or estimates from literature.

Controls and reference groups:
Critical controls should include:

• PBS-treated negative control

• Vector-only control (e.g., pCold-TF without insert)

• Positive control (e.g., B. abortus RB51 vaccine strain)

• Comparison with established recombinant protein vaccines (e.g., CSV containing Omp16, Omp19, Omp28, and L7/L12)

How can researchers integrate structural biology, biochemistry, and in vivo data to develop effective fmt-targeted therapeutics?

Developing effective fmt-targeted therapeutics requires integrating multiple data types through a systematic workflow:

Integration methodology:

• Structure-based approach initiation:

  • Obtain high-resolution crystal structures of B. abortus fmt alone and in complex with substrates

  • Identify binding pockets and catalytic residues

  • Conduct molecular dynamics simulations to understand protein flexibility, similar to studies with MetRS

• Biochemical validation and refinement:

  • Develop robust enzymatic assays to characterize kinetic parameters

  • Perform mutagenesis studies to confirm key residues

  • Screen compound libraries and characterize hit compounds

  • Optimize lead compounds through medicinal chemistry

  • Assess potential for resistance development through selection studies

• Cellular studies transition:

  • Evaluate membrane permeability and cytotoxicity

  • Determine minimum inhibitory concentrations against B. abortus

  • Assess activity in macrophage infection models (RAW 264.7 cells)

  • Measure effects on bacterial physiology (growth rate, stress responses)

• In vivo validation and development:

  • Conduct pharmacokinetic and safety studies in mice

  • Evaluate efficacy in BALB/c mouse infection model using protocols similar to those established for vaccine studies

  • Measure bacterial loads in spleen at appropriate timepoints post-infection

  • Assess therapeutic combinations with standard antibiotics

• Feedback optimization loop:

  • Use data from in vivo studies to guide further structural optimization

  • Implement iterative design-test cycles

  • Address identified limitations through structural modifications

  • Consider drug delivery systems to enhance target engagement

This integrated approach combines the strengths of structural insights, biochemical characterization, and in vivo testing to develop therapeutics with optimal properties for clinical translation.

How might recombinant B. abortus fmt contribute to improved diagnostic tools for brucellosis?

Recombinant B. abortus fmt has potential applications in developing improved diagnostics for brucellosis through several approaches:

• Serological diagnostics:

  • Development of fmt-based ELISA tests to detect specific antibodies in infected hosts

  • Potential for improved specificity compared to current LPS-based tests

  • Reduced cross-reactivity with other bacterial infections

  • Application in differentiating infected from vaccinated animals (DIVA) when used alongside other biomarkers

• Antigen detection systems:

  • Development of aptamers or antibodies against fmt for direct detection of Brucella antigens in clinical samples

  • Integration into lateral flow assays for point-of-care testing

  • Combination with other Brucella antigens in multiplex detection platforms

• Molecular diagnostics enhancement:

  • Design of fmt-specific PCR primers for species identification

  • Development of LAMP (loop-mediated isothermal amplification) assays targeting fmt for field testing

• Immunoreactivity profiling:
  Similar to the immunoblotting assays used with other recombinant Brucella proteins, fmt could be incorporated into diagnostic panels that react with Brucella-positive sera but not with negative controls .

What are the critical considerations for scaling up production of recombinant B. abortus fmt for research applications?

Scaling up production of recombinant B. abortus fmt for research applications involves several key considerations:

1. Expression system optimization:

• Evaluation of alternative expression systems beyond E. coli (Pichia pastoris, baculovirus)

• Development of codon-optimized constructs for improved expression

• Selection of optimal promoters, signal sequences, and fusion partners

• Consideration of inducible versus constitutive expression systems

2. Fermentation parameters:

• Transition from shake flask to bioreactor cultivation

• Optimization of media composition, feeding strategies, and dissolved oxygen levels

• Development of defined media formulations to ensure consistency

• Implementation of continuous monitoring and feedback control systems

3. Purification process development:

• Design of scalable chromatography protocols (expanded bed adsorption, tangential flow filtration)

• Optimization of buffer systems and elution conditions

• Development of efficient viral inactivation and removal steps if mammalian systems are used

• Implementation of high-throughput purification screening (HTPS) for parameter optimization

4. Quality control considerations:

• Development of analytical methods for identity, purity, and potency testing

• Stability studies under various storage conditions

• Endotoxin removal and testing protocols

• Batch-to-batch consistency assessment

5. Regulatory and safety aspects:

• Implementation of appropriate biosafety measures for handling recombinant Brucella proteins

• Documentation and standard operating procedures

• Material safety data sheets and risk assessments

• Shipping and storage requirements for distribution to research collaborators

What are the future research directions for B. abortus fmt as a therapeutic target?

Future research on B. abortus fmt as a therapeutic target should focus on several promising directions:

• Structural and functional characterization:

  • High-resolution structural studies of B. abortus fmt using X-ray crystallography and cryo-EM

  • Comprehensive enzymatic characterization to understand kinetic parameters and substrate specificity

  • Comparison with fmt enzymes from other bacterial pathogens to identify unique features

• Inhibitor development:

  • Fragment-based drug discovery campaigns targeting specific fmt binding pockets

  • Development of transition state analogs and mechanism-based inhibitors

  • Exploration of allosteric inhibition strategies similar to those observed with MetRS

  • Investigation of natural product scaffolds with activity against fmt

• Resistance mechanisms:

  • Study of potential resistance development through laboratory evolution experiments

  • Identification of compensatory mechanisms that might overcome fmt inhibition

  • Development of combination strategies to prevent resistance emergence

• Delivery strategies:

  • Design of targeted delivery systems to enhance intracellular accumulation in infected macrophages

  • Development of prodrug approaches to improve cellular penetration

  • Exploration of nanoparticle formulations for improved pharmacokinetics

• Alternative applications:

  • Investigation of fmt as a potential biomarker for Brucella infection

  • Development of attenuated strains with modified fmt for vaccine applications

  • Exploration of fmt inhibition in combination with immune modulation approaches